SCHEMBL4520036

SCHEMBL4520036

COc1cccc(Cn2c(=O)n(-c3cccc(OC)c3)c3nc(Nc4ccccc4)ncc32)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 15/20 0.72
ADORA1 P30542 14/20 0.72
USP2 O75604 5/20 0.68
TSHR P16473 5/20 0.68
CASP1 P29466 5/20 0.68
LMNA P02545 4/20 0.68
CYP3A4 P08684 4/20 0.68
CYP2C9 P11712 4/20 0.68
CASP7 P55210 4/20 0.68
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
CYP1A2 P05177 3/20 0.68
MAPK1 P28482 3/20 0.68
CYP2C19 P33261 3/20 0.68
CLK4 Q9HAZ1 3/20 0.68
HSD17B10 Q99714 2/20 0.68
TP53 P04637 1/20 0.68
BRCA1 P38398 1/20 0.68
HBB P68871 1/20 0.68
HIF1A Q16665 3/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519423 0.88 ADORA2A (0.86) ADORA2AADORA1
SCHEMBL13966174 0.87 ADORA2A (0.83) ADORA2AADORA1
SCHEMBL1600331 0.85 GSK3B (0.67) ADORA2AADORA1USP2TSHRCASP1
SCHEMBL13966250 0.85 ADORA2A (0.92) ADORA2AADORA1
SCHEMBL4531259 0.84 ADORA2A (0.91) ADORA2AADORA1
SCHEMBL4515959 0.84 CYP1A2 (0.66) ADORA2AADORA1USP2TSHRLMNA
SCHEMBL4520917 0.84 ADORA2A (1.00) ADORA2AADORA1
SCHEMBL4521119 0.82 ADORA2A (0.81) ADORA2AADORA1
SCHEMBL4507421 0.81 ADORA2A (0.80) ADORA2AADORA1
SCHEMBL4517277 0.81 ADORA2A (0.80) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023723-A1 Purinone derivatives for treating neurodegenerative diseases PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2009-01-22 US disclosed
US-20090023723-A1 Purinone derivatives for treating neurodegenerative diseases PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2009-01-22 US disclosed
US-20090023723-A1 Purinone derivatives for treating neurodegenerative diseases PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2009-01-22 US disclosed
WO-2007035873-A1 PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA, INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023723-A1 Purinone derivatives for treating neurodegenerative diseases ADORA2A, P2RX6, P2RX5 ADORA2A 1/4885ADORA1 9/4885USP2 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.